The FDA decision on Sanofi’s (SNY) investigational product Avalglucosidase alfa, a long-term enzyme replacement therapy, for the treatment of patients with Pompe disease, is expected on August 18.Pompe disease is a rare, degenerative muscle disorder caused by mutations in a gene that makes an enzyme called acid alpha-glucosidase (GAA). This disease can impact an individual's ability to move and breathe. About 3,500 people in the U.S. are affected by Pompe disease.Sanofi's Avalglucosidase alfa is designed to improve the delivery of acid alpha-glucosidase (GAA) enzyme to muscle cells.The current standard of care for Pompe disease is Lumizyme, which is also from the stable of Sanofi. Lumizyme sales totaled 948 million euros in 2020, up 6% over 2019.SNY closed Monday’s (Jul.26, 2021) trading at $51.63, down 0.44%.